Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2012

View Archived Issues

FGF-21 analogue fusion protein developed for treating diabetes

KinDex Therapeutics describes novel agent for diabetes

Human growth hormone analogue displays extended half-life in vivo

New triple combination therapy now available for H. pylori infection

Inovio kicks off phase I study of H1N1 vaccine

Sobi and Affibody enter new research agreement

Scientists in Taiwan discover new candidate marker of HCC prognosis

SRI International obtains Department of Defense grant

Genisphere and LIMR continue collaboration

ChemDiv Research Institute and Abbott to launch new projects

Abbott Laboratories presents novel calpain-1 inhibitors

Research in Norway yields new Wnt signaling inhibitors

Collaboration produces novel DAPD prodrugs

Lycera patents new mitochondrial F1F0 ATPase hydrolase inhibitors

New candidate dsRNA drugs discovered at Alnylam Pharmaceuticals

Novel cell migration modulators designed in Japan

Immune Response BioPharma plans phase III trial of rheumatoid arthritis vaccine

XenoPort receives grant for preclinical XP-23829 studies

Trial assessing drug for acute schizophrenia does not meet endpoint

Dosing begins in first-in-human Adipotide study

Evotec licenses molecules to Janssen

TiGenix begins enrollment in pivotal phase III trial

Noxxon launches phase IIa study in chronic lymphocytic leukemia

BioMimetic Therapeutics submits amendment to Augment bone graft PMA

Hemispherx reaches agreement with FDA on filing requirements for Ampligen NDA

Merus Labs acquires rights to drug for overactive bladder

Recruitment complete in phase III NX-1207 trial

Novel candidate hepatitis therapies divulged

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...